利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.034 秒)

    Reduction or prevention of sensitization to drugs
    3.
    发明授权
    Reduction or prevention of sensitization to drugs 失效
    减少或预防对药物的敏感性

    公开(公告)号：US5149539A

    公开(公告)日：1992-09-22

    申请号：US793936

    申请日：1991-11-15

    申请人： Philip W. Ledger ,  Michel J. N. Cormier ,  Alfred Amkraut

    发明人： Philip W. Ledger ,  Michel J. N. Cormier ,  Alfred Amkraut

    IPC分类号： A61K9/70 ,  A61K33/02

    CPC分类号： A61K9/7023 ,  A61K33/02

    摘要： The present invention is directed to a method of reducing or preventing skin sensitization by inhibiting the immunological processing of a sensitizing drug as an antigen. The drug is sensitizing to humans, i.e., the drug is susceptible to inducing skin or mucosa sensitization in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Skin sensitization reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a sensitizing drug, at a therapeutically effective rate over a predetermined period of time; and(b) an antigen processing-inhibiting agent in an amount effective to inhibit the antigen processing of the drug.The system of the invention comprises a matrix adapted to be placed in sensitizing drug and antigen processing-inhibiting agent transmitting relation to the selected skin or mucosa site. The matrix contains sufficient amounts of the drug and the agent to continuously coadminister to the skin or mucosa site the drug, at a therapeutically effective rate and over a predetermined delivery period, and the antigen processing-inhibiting agent, at a rate and for a period of time sufficient to inhibit the processing of the drug as an antigen.

    摘要翻译： 本发明涉及通过抑制作为抗原的敏化药物的免疫处理来减少或预防皮肤致敏的方法。 药物对人类敏感，即当药物以治疗有效的速率经皮给药时，药物易于引起人类皮肤或粘膜致敏。 通过向人的皮肤或粘膜共同诱导皮肤致敏减少或预防：（a）治疗有效量的敏化药物，以预定时间段的治疗有效速率; 和（b）有效抑制药物抗原加工的抗原加工抑制剂。 本发明的系统包括适于放置在致敏药物和抗原加工抑制剂中的基质，其与所选择的皮肤或粘膜部位传递关系。 基质含有足够量的药物和药剂，以治疗有效速率和超过预定的递送期间，以一定的速率和一段时间连续地连续地附着到皮肤或粘膜部位，药物，抗原加工抑制剂 的时间足以抑制作为抗原的药物的加工。

    Reduction of skin irritation and resistance during electrotransport
    5.
    发明授权
    Reduction of skin irritation and resistance during electrotransport 失效
    减少皮肤刺激和电传输期间的抵抗力

    公开(公告)号：US5624415A

    公开(公告)日：1997-04-29

    申请号：US427336

    申请日：1995-04-24

    申请人： Michel J. N. Cormier ,  Philip W. Ledger ,  Juanita Johnson ,  Joseph B. Phipps ,  Stella Chao

    发明人： Michel J. N. Cormier ,  Philip W. Ledger ,  Juanita Johnson ,  Joseph B. Phipps ,  Stella Chao

    IPC分类号： A61N1/30

    CPC分类号： A61N1/0432 ,  A61N1/0448 ,  A61N1/0436

    摘要： An electrotransport delivery device utilizing reservoir buffering at a select pH ranges in order to reduce skin irritation and skin resistance is provided. Cathodic reservoirs are buffered to a pH of less than about 4, preferably to a pH in the range of about 2 to 4, while anodic reservoirs are buffered to a pH above about 4, preferably to a pH in the range of about 4 to 10. Another electrotransport delivery device utilizes a potassium sensor to monitor potassium efflux from the skin. Potassium efflux above a certain predetermined level has been found to be a precursor to skin irritation/erythema. Operation of the device is modified (eg, terminated) when the predetermined potassium efflux level is sensed.

    摘要翻译： 提供了一种在选择的pH范围内利用储存器缓冲以便减少皮肤刺激和皮肤抵抗的电输送输送装置。 阴极储存器缓冲至小于约4的pH，优选至约2至4范围内的pH，而阳极储存器缓冲至高于约4，优选至约4至10范围内的pH 另一种电输送装置利用钾传感器来监测来自皮肤的钾流出。 已经发现高于某一预定水平的钾流出物是皮肤刺激/红斑的前体。 当检测到预定的钾流出水平时，装置的操作被修改（例如，终止）。

    Reduction or prevention of skin irritation by drugs
    7.
    发明授权
    Reduction or prevention of skin irritation by drugs 失效
    减少或预防药物对皮肤的刺激

    公开(公告)号：US5160741A

    公开(公告)日：1992-11-03

    申请号：US793932

    申请日：1991-11-13

    申请人： Michel J. N. Cormier ,  Philip W. Ledger ,  Alfred Amkraut

    发明人： Michel J. N. Cormier ,  Philip W. Ledger ,  Alfred Amkraut

    IPC分类号： A61K47/02 ,  A61K47/18

    CPC分类号： A61K31/70 ,  A61K47/02 ,  A61K47/18 ,  A61K9/0014

    摘要： The present invention provides a method of reducing or preventing skin irritation of a weak base drug by inhibiting the accumulation of the drug in the lysosomes. The drug is irritating to humans, i.e., the drug is susceptible to inducing skin or mucosa irritation in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Irritation reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and(b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.

    摘要翻译： 本发明提供了通过抑制药物在溶酶体中的积累来减少或预防弱碱性药物的皮肤刺激的方法。 该药物对人类有刺激性，即当药物以治疗有效率透皮给药时，该药物易于引起人体皮肤或粘膜刺激。 通过向人的皮肤或粘膜共同诱导刺激减少或预防：（a）在预定时间段内以治疗有效速率治疗有效量的对人类有刺激性的弱碱性药物; 和（b）有效量的能够抑制药物的溶酶体摄取以减少或防止对皮肤或粘膜的刺激​​的药剂。

    Formulations for the administration of fluoxetine
    9.
    发明授权
    Formulations for the administration of fluoxetine 失效
    氟西汀治疗剂型

    公开(公告)号：US06512010B1

    公开(公告)日：2003-01-28

    申请号：US08892118

    申请日：1997-07-14

    申请人： Robert M. Gale ,  Melinda K. Nelson ,  Michel J. N. Cormier ,  Suneel K. Gupta ,  Patricia S. Campbell

    发明人： Robert M. Gale ,  Melinda K. Nelson ,  Michel J. N. Cormier ,  Suneel K. Gupta ,  Patricia S. Campbell

    IPC分类号： A61K3135

    CPC分类号： A61K9/7084 ,  A61K31/135 ,  A61K31/138 ,  A61K31/57 ,  A61K2300/00

    摘要： Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

    摘要翻译： 用于通过穿过身体表面或膜透过体外表面或膜施用氟西汀的物质的组成，所述组合物包含单独或与渗透促进剂或混合物组合的待施用氟西汀。 优选的实施方案涉及在减少的皮肤刺激水平下透皮给药氟西汀，其中氟西汀，优选以醋酸氟西汀提供，与皮质类固醇如氢化可的松共同施用。 还公开了含有氟西汀或氟西汀和增强剂组合物的药物递送装置和用于透皮给药氟西汀和氟西汀/增强剂组合物的方法。